PCPhyllis Chan

Phyllis Chan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Phyllis Chan has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A systematic review and meta-analysis of physician resident burnout in Egypt

    by Abdelrahman M. Makram, Phyllis Chan, Samantha Alvarez-Madrazo, Celine Tabche

    Background: Physician resident burnout in Egypt represents a critical concern for the well-being of healthcare professionals and the quality of patient care. This systematic review and meta-analysis aimed to comprehensively assess the prevalence, severity, and key risk factors contributing to burnout among physician residents in Egypt over the past decade. Methods: We searched five databases (Ovid Medline, Embase, APA PsycInfo, Scopus, and Web of Science) in May 2024 for studies that examined burnout prevalence, severity, and/or associated risk factors in Egypt among physician residents or bachelor’s degree holders in medicine. We excluded articles that investigated the causes of burnout in senior physicians, such as specialists, as well as articles that investigated the causes of burnout in other healthcare workers. The prevalence was pooled using generalized linear mixed models while the scores of each Maslach Burnout Inventory (MBI) element (depersonalization [DP], emotional exhaustion [EE], and reduced personal accomplishment [RPA]) were estimated using the log-transformed mean differences. All values are presented along with the 95% confidence interval (CI). Results: The review included eleven studies with 804 resident physicians. The meta-analysis included only nine studies. Three studies reported that 84% [95%-CI: 44–97%] of physician residents experienced burnout, with 67% [95%-CI: 44–85%], 73% [95%-CI: 48–89%], and 54% [95%-CI: 39–68%] having high DP, EE, and RPA, respectively. One study provided an overall Maslach Burnout Index score with a mean of 29.8 (SD = 4.8), while five others reported mean scores for DP (17.64, 95%-CI: 12.85–24.23), EE (32.09, 95%-CI: 27.76–37.08), and RPA (27.89, 95%-CI: 24.93–31.22). Key risk factors included long working hours, job stress, depression, and workplace violence. Conclusion: Although our review emphasized the high prevalence of burnout among physician residents in Egypt, the heterogeneity observed in the reporting of the results of the included studies might contribute to an overestimation of the true prevalence of burnout, underscoring the need for further research in the field. Nonetheless, the need for systemic reforms remains unquestionable, including workload reduction, improved work-life balance, standardized training, merit-based advancement, and anti-abuse policies.

  • Open Access

    Current State‐of‐the‐Art and Future Advancements of Model‐Based Meta‐Analysis

    by Phyllis Chan, Monica Simeoni, Matthew L. Zierhut, John Maringwa, Jonathan French

  • Open Access

    Model‐Based Meta‐Analysis of Overall Survival in Vulnerable Platinum‐Ineligible NSCLC Populations

    by Joseph Chen, Russ Wada, Nancy Zhang, Vilma Graupner, Stefanie Morris, Youyou Hu, Wei Zhang, Nastya Kassir, Benjamin Wu, Phyllis Chan

    IPSOS (NCT03191786) is a Phase III trial comparing atezolizumab (atezo) monotherapy to single‐agent chemotherapy (gemcitabine or vinorelbine) in patients with treatment‐naïve locally advanced or metastatic NSCLC unsuitable for platinum‐doublet chemotherapy. The study demonstrated significant overall survival (OS) improvement in the atezo arm compared to single‐agent chemotherapy, with a stratified hazard ratio (HR) of 0.78 (95% CI: 0.63–0.97; p = 0.028). Since the IPSOS control arm only allowed gemcitabine or vinorelbine, a model‐based meta‐analysis (MBMA) was conducted, extracting OS data from published literature in similar patients, adjusting for population differences across trials, to estimate the HR between IPSOS arms versus historical trials which utilized single‐agent chemotherapies. The aim was to demonstrate the non‐inferiority of the IPSOS control arm versus historical controls. The literature search included patients who were chemotherapy‐naïve, had advanced or metastatic NSCLC, were platinum‐ineligible, ≥ 70 years or had ECOG ≥ 2, and were treated with single‐agent paclitaxel, docetaxel, gemcitabine, pemetrexed, or vinorelbine. Summary‐level OS data were extracted by digitizing Kaplan‐Meier curves, resulting in a database of 26 trials with 41 arms and 3637 participants. A nonparametric approach modeling the conditional probability of OS data was implemented. After adjusting for ECOG PS (the only significant covariate), the model‐predicted HR for the IPSOS control arm relative to historical trials was 0.543 (95% CI: 0.435–0.677), and the HR for the IPSOS atezo monotherapy arm was 0.418 (95% CI: 0.335–0.522). Overall, the MBMA results support the benefit of atezo seen in the IPSOS trial.


  • Open Access

    Revisiting the Anti-Drug Antibody Assay Drug Tolerance of a Commercial Biological Product

    by James Zanghi, Nancy Yu, Benjamin T. Andrews, Phyllis Chan, Maxime Usdin, Cecilia Chiu, WeiYu Lin, Alyse Lin, Yuan Song

    Drug tolerance (DT) is a critical attribute of anti-drug antibody (ADA) assays for assessing clinical immunogenicity. We present a unique situation where a previously approved commercial product, atezolizumab, required re-assessment of the assay DT to meet an increased drug exposure demand arising from a new route of administration (subcutaneous) and align with updated health authority (HA) regulations. Rather than redevelop the existing ADA assay, which could disrupt ongoing clinical trials, we identified a new anti-idiotype (anti-ID) antibody surrogate that demonstrated that the assay maintained adequate DT for the new route of administration. This streamlined approach addressed concerns regarding higher serum trough concentrations with subcutaneous administration and stricter sensitivity expectations. We established a target DT concentration based on population pharmacokinetic modeling to ensure adequate ADA characterization at steady state. This case study highlights the value of having alternative surrogate ADAs and demonstrates that achieving stringent DT requirements can be accomplished without extensive method redevelopment. We also introduce the broader implications of surrogate ADA selection, binding kinetics, and the clinical relevance of achieving high DT in the context of atezolizumab's efficacy and safety profile. This work also emphasizes the importance of considering bioanalytical assay characteristics, such as DT, throughout a product’s lifecycle. Graphical Abstract


  • Open Access

    Supplementary Data from Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150

    by René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, et al.

  • Open Access

    Data from Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150

    by René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, et al.

    Purpose:Model-based tumor growth inhibition (TGI) metrics are increasingly incorporated into go/no-go decisions in early clinical studies. To apply this methodology to new investigational combinations requires independent evaluation of TGI metrics in recently completed Phase III trials of effective immunotherapy.Patients and Methods:Data were extracted from IMpower150, a positive, randomized, Phase III study of first-line therapy in 1,202 patients with non–small cell lung cancer. We resampled baseline characteristics and longitudinal sum of longest diameters of tumor lesions of patients from both arms, atezolizumab+ bevacizumab+chemotherapy (ABCP) versus BCP, to mimic Phase Ib/II studies of 15 to 40 patients/arm with 6 to 24 weeks follow-up. TGI metrics were estimated using a bi-exponential TGI model. Effect sizes were calculated as TGI metrics ratio of medians (MedR), objective response rate (ORR) difference (d), and progression-free survival (PFS), hazard ratio (HR) between arms. Correct and incorrect go decisions were evaluated as the probability to achieve desired effect sizes in ABCP versus BCP and BCP versus BCP, respectively, across 500 replicated subsamples for each design.Results:For 40 patients/24 weeks follow-up, correct go decisions based on probability tumor growth rate (KG) MedR 0.10, and PFS HR <0.70 were 83%, 69%, and 58% with incorrect go decision rates of 4%, 12%, and 11%, respectively. For other designs, the ranking did not change with TGI metrics consistently overperforming RECIST endpoints. The predicted overall survival (OS) HR was around 0.80 in most of the scenarios investigated.Conclusions:Model-based estimate of KG MedR is an exploratory endpoint that informs early clinical decisions for combination studies.

  • Open Access

    Population Pharmacokinetics and Exposure‐Response of Subcutaneous Atezolizumab in Patients With Non‐Small Cell Lung Cancer

    by Phyllis Chan, Stephanie N. Liu, Nathalie Gosselin, Zacharie Sauve, Mathilde Marchand, Alyse Lin, Luis Herraez‐Baranda, James Zanghi, Esther Shearer‐Kang, Xiaoyan Liu, et al.

    IMscin001 is a two‐part dose‐finding (Phase Ib) and ‐confirmation (Phase III) study to evaluate atezolizumab pharmacokinetics of subcutaneous (SC) compared with intravenous (IV) administration in patients with locally advanced or metastatic non‐small cell lung cancer (NSCLC). The objectives of the current analyses were to characterize the population pharmacokinetics (popPK) of atezolizumab and to determine the relationship between atezolizumab exposure and safety and efficacy endpoints in IMscin001. A previously validated IV popPK model was extended to add SC absorption parameters using SC and IV data from Phase Ib and Phase III of IMscin001 (N = 435), and covariate effects were investigated on the SC absorption parameters. The exposure‐response (ER) investigation was performed using SC data following 1875 mg every three weeks (q3w) administration in the Phase III portion of IMscin001 (N = 246). The clinical endpoints were objective response rate, progression‐free survival, or overall survival for efficacy, serious adverse events, special interest adverse events, Grades 3–5 adverse events, infusion‐related reaction, or injection site reactions for safety. Atezolizumab SC absorption was characterized by a first‐order absorption with a bioavailability of 71.8% and an absorption rate constant of 0.304 day−1. The extended popPK model was adequate to predict atezolizumab PK after IV and SC administrations and to predict individual exposure metrics. For all efficacy and safety endpoints, atezolizumab exposure was not statistically significant (p‐value > 0.05) in the ER models. The non‐inferior popPK exposure and flat ER results supported atezolizumab SC dose at 1875 mg q3w.


  • Open Access

    Comparison of two‐stage and joint TGI‐OS modeling using data from six atezolizumab clinical studies in patients with metastatic non‐small cell lung cancer

    by Antonio Gonçalves, Mathilde Marchand, Phyllis Chan, Jin Y. Jin, Jérémie Guedj, René Bruno

    Two‐stage and joint modeling approaches are the two main approaches to investigate the link between longitudinal tumor size data and overall survival (OS) and anticipate clinical trial outcome. We here used a large database composed of one phase II and five phase III clinical trials evaluating atezolizumab (an immunotherapy) in monotherapy or in combination with chemotherapies in 3699 patients with non‐small cell lung cancer to evaluate the differences between both approaches in terms of parameter estimates, magnitude of covariate effects, and ability to predict OS. Although the two‐stage approach may underestimate the magnitude of the impact of tumor growth rate (KG) on OS compared to joint modeling approach (hazard ratios [HRs] of 0.42–2.52 vs. 0.25–2.85, respectively, for individual KG varying from the 5th and 95th percentiles), this difference did not lead into poorer performance of the two‐stage approach to describe the OS distribution in the six clinical studies. Overall, two‐stage and joint modeling approaches accurately predicted OS HR with a median (range) difference with the observed OS HR of 0.02 (0.01–0.18) and 0.03 (0.00–0.19), in all cases considered, respectively (e.g., for IMpower150: 0.80 [0.66–0.95] vs. 0.82 [0.70–0.95], respectively, whereas the observed OS HR was 0.80). In our setting, the two‐stage approach accurately predicted the benefit of atezolizumab on OS. Further work is needed to verify if similar results are achieved using phase Ib or phase II clinical trials where the number of patients and measurements is limited as well as in other cancer indications.


  • Open Access

    Data from Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150

    by René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, et al.

    Purpose:Model-based tumor growth inhibition (TGI) metrics are increasingly incorporated into go/no-go decisions in early clinical studies. To apply this methodology to new investigational combinations requires independent evaluation of TGI metrics in recently completed Phase III trials of effective immunotherapy.Patients and Methods:Data were extracted from IMpower150, a positive, randomized, Phase III study of first-line therapy in 1,202 patients with non–small cell lung cancer. We resampled baseline characteristics and longitudinal sum of longest diameters of tumor lesions of patients from both arms, atezolizumab+ bevacizumab+chemotherapy (ABCP) versus BCP, to mimic Phase Ib/II studies of 15 to 40 patients/arm with 6 to 24 weeks follow-up. TGI metrics were estimated using a bi-exponential TGI model. Effect sizes were calculated as TGI metrics ratio of medians (MedR), objective response rate (ORR) difference (d), and progression-free survival (PFS), hazard ratio (HR) between arms. Correct and incorrect go decisions were evaluated as the probability to achieve desired effect sizes in ABCP versus BCP and BCP versus BCP, respectively, across 500 replicated subsamples for each design.Results:For 40 patients/24 weeks follow-up, correct go decisions based on probability tumor growth rate (KG) MedR 0.10, and PFS HR <0.70 were 83%, 69%, and 58% with incorrect go decision rates of 4%, 12%, and 11%, respectively. For other designs, the ranking did not change with TGI metrics consistently overperforming RECIST endpoints. The predicted overall survival (OS) HR was around 0.80 in most of the scenarios investigated.Conclusions:Model-based estimate of KG MedR is an exploratory endpoint that informs early clinical decisions for combination studies.

  • Open Access

    Supplementary Data from Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150

    by René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, et al.